Articles with public access mandates - Amit MahipalLearn more
Not available anywhere: 4
Isocitrate dehydrogenase–mutated cholangiocarcinoma: Natural history and clinical outcomes
G Wintheiser, T Zemla, Q Shi, N Tran, K Prasai, SH Tella, K Mody, D Ahn, ...
JCO Precision Oncology 6, e2100156, 2022
Mandates: Pancreatic Cancer Action Network, USA
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
PLS Uson Junior, TT DeLeon, JM Bogenberger, RK Pai, HE Kosiorek, ...
Digestive diseases and sciences, 1-9, 2022
Mandates: US National Institutes of Health
Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications
LA Kankeu Fonkoua, PL Serrano Uson Junior, K Mody, A Mahipal, ...
Expert opinion on therapeutic targets 26 (1), 79-92, 2022
Mandates: US National Institutes of Health
Outcomes following FGFR inhibitor therapy in patients with cholangiocarcinoma
JJ Gile, V Wookey, TJ Zemla, Q Shi, Z Jin, SR Alberts, RR McWilliams, ...
Targeted Oncology 17 (5), 529-538, 2022
Mandates: US National Institutes of Health
Available somewhere: 39
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE …
LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ...
Journal of Clinical Oncology 34 (32), 3838-3845, 2016
Mandates: US National Institutes of Health
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ...
New England Journal of Medicine 388 (3), 228-239, 2023
Mandates: US National Institutes of Health
First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors
AR Abdul Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, ...
Journal of Clinical Oncology 34 (34), 4142-4150, 2016
Mandates: US National Institutes of Health
Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis
MB Sonbol, IB Riaz, SAA Naqvi, DR Almquist, S Mina, J Almasri, S Shah, ...
JAMA oncology 6 (12), e204930-e204930, 2020
Mandates: US National Institutes of Health
First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy
P Munster, M Mita, A Mahipal, J Nemunaitis, C Massard, T Mikkelsen, ...
Cancer management and research, 10463-10476, 2019
Mandates: US National Institutes of Health, Government of Spain
Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer
S Kazim, MP Malafa, D Coppola, K Husain, S Zibadi, T Kashyap, ...
Molecular cancer therapeutics 14 (7), 1570-1581, 2015
Mandates: US National Institutes of Health
Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites
A Mahipal, J Klapman, S Vignesh, CS Yang, A Neuger, DT Chen, ...
Cancer chemotherapy and pharmacology 78, 157-165, 2016
Mandates: US National Institutes of Health
The promise of circulating tumor DNA (ctDNA) in the management of early-stage colon cancer: a critical review
S Chakrabarti, H Xie, R Urrutia, A Mahipal
Cancers 12 (10), 2808, 2020
Mandates: US National Institutes of Health
Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma
AS Azmi, HY Khan, I Muqbil, A Aboukameel, JE Neggers, D Daelemans, ...
Clinical Cancer Research 26 (6), 1338-1348, 2020
Mandates: US National Institutes of Health
PET/CT fusion scan prevents futile laparotomy in early stage pancreatic cancer
R Kim, G Prithviraj, N Kothari, G Springett, M Malafa, P Hodul, J Kim, ...
Clinical nuclear medicine 40 (11), e501-e505, 2015
Mandates: US National Institutes of Health
Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: an analysis of the ACCENT database
Z Jin, JG Dixon, JM Fiskum, HD Parekh, FA Sinicrope, G Yothers, ...
JNCI: Journal of the National Cancer Institute 113 (12), 1693-1704, 2021
Mandates: US National Institutes of Health
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1
A Mahipal, S Ejadi, S Gnjatic, S Kim-Schulze, H Lu, JH Ter Meulen, ...
Cancer Immunology, Immunotherapy 68, 1211-1222, 2019
Mandates: US National Institutes of Health
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
E Wolin, A Mita, A Mahipal, T Meyer, J Bendell, J Nemunaitis, PN Munster, ...
PLoS One 14 (9), e0221994, 2019
Mandates: Cancer Research UK, National Institute for Health Research, UK
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers
TL Hogenson, H Xie, WJ Phillips, MD Toruner, JJ Li, IP Horn, DJ Kennedy, ...
JCI insight 7 (22), 2022
Mandates: US National Institutes of Health
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
H Park, GI Shapiro, X Gao, A Mahipal, J Starr, M Furqan, P Singh, ...
ESMO open 7 (5), 100573, 2022
Mandates: US National Institutes of Health
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga
SM Thompson, G Suman, MS Torbenson, ZME Chen, DE Jondal, A Patra, ...
Hepatology Communications 6 (5), 1172-1185, 2022
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program